Jamie Deutsch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jamie Deutsch has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Crompton
Department of Microbiology and Molecular Genetics, University of Vermont, Burlington, VT 05405, USA
1 shared publication - David J. Argyle
Royal (Dick) School of Veterinary Studies and Roslin Institute, Easter Bush, Midlothian EH25 9RG, UK
1 shared publication - Dmitry M. Korzhnev
Department of Molecular Biology and Biophysics, University of Connecticut Health Center, Farmington, USA
1 shared publication - Erica N. Lamkin
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA
1 shared publication - Jiyong Hong
Department of Chemistry, Duke University, Durham, USA
1 shared publication - Kanayo Ikeh
Department of Microbiology and Molecular Genetics, University of Vermont, Burlington, VT 05405, USA
1 shared publication
Latest Publications
- Open Access
REV1 Inhibition Enhances Radioresistance and Autophagy
Cancer therapy resistance is a persistent clinical challenge. Recently, inhibition of the mutagenic translesion synthesis (TLS) protein REV1 was shown to enhance tumor cell response to chemotherapy by triggering senescence hallmarks. These observations suggest REV1’s important role in determining cancer cell response to chemotherapy. Whether REV1 inhibition would similarly sensitize cancer cells to radiation treatment is unknown. This study reports a lack of radiosensitization in response to REV1 inhibition by small molecule inhibitors in ionizing radiation-exposed cancer cells. Instead, REV1 inhibition unexpectedly triggers autophagy, which is a known biomarker of radioresistance. We report a possible role of the REV1 TLS protein in determining cancer treatment outcomes depending upon the type of DNA damage inflicted. Furthermore, we discover that REV1 inhibition directly triggers autophagy, an uncharacterized REV1 phenotype, with a significant bearing on cancer treatment regimens.
Open AccessREV1 Inhibition Enhances Radioresistance and Autophagy
Cancer therapy resistance is a persistent clinical challenge. Recently, inhibition of the mutagenic translesion synthesis (TLS) protein REV1 was shown to enhance tumor cell response to chemotherapy by triggering senescence hallmarks. These observations suggest REV1’s important role in determining cancer cell response to chemotherapy. Whether REV1 inhibition would similarly sensitize cancer cells to radiation treatment is unknown. This study reports a lack of radiosensitization in response to REV1 inhibition by small molecule inhibitors in ionizing radiation-exposed cancer cells. Instead, REV1 inhibition unexpectedly triggers autophagy, which is a known biomarker of radioresistance. We report a possible role of the REV1 TLS protein in determining cancer treatment outcomes depending upon the type of DNA damage inflicted. Furthermore, we discover that REV1 inhibition directly triggers autophagy, an uncharacterized REV1 phenotype, with a significant bearing on cancer treatment regimens.